{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:25:42Z","timestamp":1790706342378,"version":"4.1.0"},"reference-count":207,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,15]]},"DOI":"10.1097\/01.tp.0000219703.39149.85","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T04:38:56Z","timestamp":1147235936000},"page":"1234-1248","source":"Crossref","is-referenced-by-count":286,"title":["Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1097","volume":"81","author":[{"given":"Angela C.","family":"Webster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent W. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210129","article-title":"2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994\u20132003.","year":"2004"},{"key":"R2-3-20210129","first-page":"65","article-title":"ANZDATA Registry Report 2003.","author":"Chadban","year":"2003"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4049\/jimmunol.144.1.251","article-title":"Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.","volume":"144","author":"Dumont","year":"1990","journal-title":"J Immunol"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: A review of the evidence.","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine.","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplantation"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2249.1997.d01-984.x","article-title":"Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.","volume":"108","author":"Stepkowski","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007890-200002270-00006","article-title":"SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts.","volume":"69","author":"Viklicky","year":"2000","journal-title":"Transplantation"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study\u2014The Rapamune U.S. Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"RAPAMUNE Global Study Group: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"issue":"suppl 1","key":"R10-3-20210129","first-page":"474","article-title":"International, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with neoral and steroids [abstract].","volume":"1","author":"Vitko","year":"2001","journal-title":"Am J Transplant"},{"key":"R11-3-20210129","first-page":"762","article-title":"The pleiotropic effects of mTor inhibitors.","volume":"17","author":"Ponticelli","year":"2004","journal-title":"J Nephrol"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients.","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews.","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R15-3-20210129","first-page":"285","article-title":"Systematic reviews in healthcare [ed. 2].","author":"Deeks","year":"2001"},{"issue":"suppl 5","key":"R16-3-20210129","first-page":"465","article-title":"A comparative, open-label study to evaluate graft function in de novo renal allograft recipients treated with reduced-dose or standard-dose cyclosporine in combination with sirolimus and corticosteroids [abstract].","volume":"3","author":"Cohen","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 2","key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007890-200407271-00598","article-title":"Use of sirolimus as initial therapy after renal transplantation: Preliminary results of a randomized pilot study in patient receiving marginal kidneys.","volume":"78","author":"Durrbach","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 5","key":"R18-3-20210129","first-page":"463","article-title":"A prospective randomized single center study of rapid corticosteroid elimination comparing two maintenance immunosuppressive protocols: Tacrolimus (FK506)\/mycophenolate mofetil (MMF) versus tacrolimus\/sirolimus [abstract].","volume":"3","author":"Gallon","year":"2003","journal-title":"Am J Transplant"},{"issue":"suppl 8","key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00007890-200407271-01242","article-title":"Preliminary results of a randomized trial comparing sirolimus (srl) versus cyclosporine (csa) in 150 transplant patients receiving a cadaveric renal graft.","volume":"78","author":"Lebranchu","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 5","key":"R20-3-20210129","first-page":"351","article-title":"Concentration-controlled use of sirolimus (SRL) associated with reduced exposure of cyclosporine (CSA) in black patients [abstract].","volume":"3","author":"Machado","year":"2003","journal-title":"Am J Transplant"},{"issue":"suppl 8","key":"R21-3-20210129","first-page":"251","article-title":"Pharmacokinetics, safety and efficacy of mycophenolate mofetil in combination with sirolimus vs cyclosporine in renal transplant patients.","volume":"4","author":"Pescovitz","year":"2004","journal-title":"Am J Transplant"},{"issue":"suppl","key":"R22-3-20210129","first-page":"916","article-title":"Assessment of renal function in de novo renal transplant patients receiving either sirolimus or everolimus in addition to cyclosporine a [abstract].","volume":"12","author":"Rostaing","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 5","key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients.","volume":"35","author":"Russ","year":"2003","journal-title":"Transplant Proc"},{"issue":"suppl 2","key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00007890-200407271-00299","article-title":"Tacrolimus in combination with two different sirolimus doses versus a tacrolimus\/mmf-based regimen: A large, randomised clinical study in renal transplantation.","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: An interim analysis.","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"Am J Transplant"},{"issue":"suppl 1","key":"R26-3-20210129","first-page":"475","article-title":"North\/South American, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with neoral and corticosteroids [abstract].","volume":"1","author":"Kaplan","year":"2001","journal-title":"Am J Transplant"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine.","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"suppl","key":"R28-3-20210129","first-page":"101","article-title":"A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time: Initial results [abstract].","volume":"13","author":"Grinyo","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine\u2014Sirolimus European Renal Transplant Study Group.","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"issue":"suppl 5","key":"R31-3-20210129","first-page":"350","article-title":"Comparison of tacrolimus (FK506) and sirolimus (SRL) combination with FK506 and mycophenolate mofetil (MMF) in kidney transplant recipients with steroid avoidance [abstract].","volume":"3","author":"Kumar","year":"2003","journal-title":"Am J Transplant"},{"issue":"suppl 5","key":"R32-3-20210129","first-page":"563","article-title":"Sirolimus prolongs delayed graft function in recipients of sub-optimal cadaveric kidney donors [abstract].","volume":"3","author":"Stallone","year":"2003","journal-title":"Am J Transplant"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"Rad in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection.","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial\u2014Rapamune Study Group.","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"suppl 3","key":"R35-3-20210129","first-page":"274","article-title":"Defining the optimal doses of sirolimus and tacrolimus in high-risk cadaveric renal transplant recipients [abstract].","volume":"2","author":"Gaber","year":"2002","journal-title":"Transplantation"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months.","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"issue":"suppl 4","key":"R37-3-20210129","first-page":"786","article-title":"Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced neoral exposure and basiliximab: 6 months analysis [abstract].","volume":"18","author":"Kramer","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0041-1345(00)02421-0","article-title":"A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.","volume":"33","author":"Machado","year":"2001","journal-title":"Transplant Proc"},{"issue":"suppl 5","key":"R39-3-20210129","first-page":"464","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus +steroids compared to reduced-dose tacrolimus sirolimus + steroids in renal allograft recipients [abstract].","volume":"3","author":"Paczek","year":"2003","journal-title":"Am J Transplant"},{"issue":"suppl 4","key":"R40-3-20210129","first-page":"786","article-title":"Excellent renal function with concentration-controlled everolimus, reduced exposure to neoral, and steroids in de novo kidney transplant recipients: Results of a 6 months efficacy and safety analysis [abstract].","volume":"18","author":"Pascual","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/01.TP.0000071301.86299.75","article-title":"A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.","volume":"75","author":"van Hooff","year":"2003","journal-title":"Transplantation"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/00007890-200212150-00013","article-title":"Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.","volume":"74","author":"Gonwa","year":"2002","journal-title":"Transplantation"},{"issue":"suppl 3","key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0041-1345(03)00226-4","article-title":"Kidney transplantation without calcineurin inhibitors using sirolimus.","volume":"35","author":"Stegall","year":"2003","journal-title":"Transplant Proc"},{"issue":"suppl 11","key":"R44-3-20210129","first-page":"463","article-title":"6 months preliminary results of a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a cadaveric renal graft.","volume":"5","author":"Glotz","year":"2005","journal-title":"Am J Transplant"},{"key":"R45-3-20210129","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation.","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"suppl 5","key":"R47-3-20210129","first-page":"465","article-title":"Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection [abstract].","volume":"3","author":"Miller","year":"2003","journal-title":"Am J Transplant"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation\u2014Modification of Diet in Renal Disease Study Group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R49-3-20210129","first-page":"43","article-title":"Systematic reviews in health care [ed. 2].","author":"Egger","year":"2001"},{"key":"R50-3-20210129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"R51-3-20210129","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1600-6143.2004.00484.x","article-title":"Surrogate markers for long-term renal allograft survival.","volume":"4","author":"Hariharan","year":"2004","journal-title":"Am J Transplant"},{"key":"R52-3-20210129","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1600-6135.2003.00275.x","article-title":"Poor predictive value of serum creatinine for renal allograft loss.","volume":"3","author":"Kaplan","year":"2003","journal-title":"Am J Transplant"},{"key":"R53-3-20210129","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.TP.0000060740.69785.09","article-title":"Predicting long-term kidney graft survival: Can new trials be performed?","volume":"75","author":"Paraskevas","year":"2003","journal-title":"Transplantation"},{"key":"R54-3-20210129","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management.","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"R55-3-20210129","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1600-6143.2005.00931.x","article-title":"Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials.","volume":"5","author":"Mulay","year":"2005","journal-title":"Am J Transplant"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9210","article-title":"Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study.","volume":"9","author":"Woodroffe","year":"2005","journal-title":"Health Technol Assess"},{"key":"R57-3-20210129","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.TP.0000144181.47045.FE","article-title":"A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.","volume":"78","author":"Gallagher","year":"2004","journal-title":"Transplantation"},{"key":"R58-3-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996.","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"R59-3-20210129","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1600-6143.2005.00853.x","article-title":"Long-term deterioration of kidney allograft function.","volume":"5","author":"Kasiske","year":"2005","journal-title":"Am J Transplant"},{"key":"R60-3-20210129","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/j.1600-6143.2005.01019.x","article-title":"Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.","volume":"5","author":"Meier-Kriesche","year":"2005","journal-title":"Am J Transplant"},{"key":"R61-3-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1523-1755.2002.00424.x","article-title":"Post-transplant renal function in the first year predicts long-term kidney transplant survival.","volume":"62","author":"Hariharan","year":"2002","journal-title":"Kidney Int"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007890-200407271-00598","article-title":"Use of sirolimus as initial therapy after renal transplantation: Preliminary results of a randomized pilot study in patient receiving marginal kidneys abstract.","volume":"78","author":"Durrbach","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"345","article-title":"Use of sirolimus as initial therapy after renal transplantation: Preliminary results of a randomized pilot study in patient receiving marginal kidneys abstract.","volume":"4","author":"Thervet","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"450","article-title":"A randomized prospective trial of sirolimus vs. cyclosporine in kidney transplantation: Renal function and histology at two years abstract.","volume":"3","author":"Flechner","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine.","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00007890-200407271-00374","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs abstract.","volume":"78","author":"Flechner","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"-20210129","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.","volume":"4","author":"Flechner","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","first-page":"274","article-title":"Defining the optimal doses of sirolimus and tacrolimus in high-risk cadaveric renal transplant recipients abstract.","volume":"2","author":"Gaber","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation.","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0041-1345(03)00238-0","article-title":"Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients.","volume":"35","author":"Lo","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","article-title":"Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.","volume":"18","author":"Lo","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"suppl 11","key":"-20210129","first-page":"288","article-title":"Prospective randomized single center study comparing the impact on long term renal transplant function of two prednisone free maintenance immunosuppressive combinations with tacrolimus (Tac), mycophenolate mofetil (MMF) versus tacrolimus\/sirolimus (SLR) abstract.","volume":"5","author":"Gallon","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"463","article-title":"A prospective randomized single center study of rapid corticosteroid elimination comparing two maintenance immunosuppressive protocols: Tacrolimus (FK506)\/mycophenolate mofetil (MMF) versus tacrolimus\/sirolimus abstract.","volume":"3","author":"Gallon","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 11","key":"-20210129","first-page":"460","article-title":"6 months preliminary results of a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a cadaveric renal graft abstract.","volume":"5","author":"Glotz","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"-20210129","first-page":"208","article-title":"Sirolimus-treated renal transplant recipients experience improved renal function with cyclosporine elimination: One-year results from a phase II trial abstract.","volume":"16","author":"Campistol","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00958","article-title":"Sirolimus (Rapamune) permits early elimination of cyclosporine in recipients of cadaveric renal allografts abstract.","volume":"69","author":"Gonwa","year":"2000","journal-title":"Transplantation"},{"issue":"11","key":"-20210129","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/00007890-200212150-00013","article-title":"Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.","volume":"74","author":"Gonwa","year":"2002","journal-title":"Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"891","article-title":"Sirolimus (srl) treated patients demonstrate improved renal function after withdrawal of cyclosporine (csa) abstract.","volume":"12","author":"Gonwa","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months.","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00007890-200407271-00698","article-title":"One year results for the first prospective multi-center kidney transplant study comparing tacrolimussirolimus vs. tacrolimusmmf combination therapy abstract.","volume":"78","author":"Gonwa","year":"2004","journal-title":"Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"101","article-title":"A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time: Initial results abstract.","volume":"13","author":"Grinyo","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl 3","key":"-20210129","first-page":"394","article-title":"A randomised, open-label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. preliminary results abstract.","volume":"2","author":"Grinyo","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1600-6143.2004.00499.x","article-title":"Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.","volume":"4","author":"Grinyo","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0041-1345(03)00213-6","article-title":"Bicentre hospital experience with sirolimus-based therapy in human renal transplantation: The Sirolimus European Renal Transplant Study.","volume":"35","author":"Charpentier","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"-20210129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporineSirolimus European Renal Transplant Study Group.","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/S0041-1345(98)01341-4","article-title":"New trails in transplantation: How to exploit the potential of sirolimus in clinical transplantation.","volume":"30","author":"Groth","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0041-1345(03)00241-0","article-title":"Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation.","volume":"35","author":"Legendre","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007890-200004271-00976","article-title":"Comparison of long term csa - and sirolimus-based therapies on lipid parameters abstract.","volume":"69","author":"Legendre","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.","volume":"2","author":"Morales","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00007890-200004271-00954","article-title":"Multicenter, randomized, double-blind, dose-finding study evaluating the efficacy and safety of rad001 (rad) in de novo renal transplant recipients abstract.","volume":"69","author":"Kahan","year":"2000","journal-title":"Transplantation"},{"issue":"10","key":"-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"suppl 1","key":"-20210129","first-page":"475","article-title":"Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials abstract.","volume":"1","author":"Kovarik","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"-20210129","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/S0041-1345(98)01341-4","article-title":"New trails in transplantation: How to exploit the potential of sirolimus in clinical transplantation.","volume":"30","author":"Groth","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"-20210129","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trialRapamune Study Group.","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants.","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology Therapeutics"},{"issue":"6","key":"-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model.","volume":"2","author":"Blum","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"289","article-title":"Sirolimus (Rapamune): Effects on bone in renal transplant patients abstract.","volume":"69","author":"Campistol","year":"2000","journal-title":"Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"880","article-title":"The effect of sirolimus on lipids on renal transplant recipients: Results from clinical trials abstract.","volume":"12","author":"Campistol","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"-20210129","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","article-title":"Rapamycin: Clinical results and future opportunities.","volume":"72","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants.","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology Therapeutics"},{"issue":"9225","key":"-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre studyThe Rapamune U.S. Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"issue":"9225","key":"-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre studyThe Rapamune U.S. Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation.","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"suppl 1","key":"-20210129","first-page":"324","article-title":"Multi-center phase ii trial of sirolimus in renal transplantation: Safety and efficacy for black patients abstract.","volume":"3","author":"Neylan","year":"1997","journal-title":"Nephrology"},{"issue":"suppl","key":"-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00007890-199904150-00948","article-title":"Effect of race on efficacy safety of Sirolimus vs. AZA standard immunotherapy in renal transplantation abstract.","volume":"67","author":"Neylan","year":"1999","journal-title":"Transplantation"},{"issue":"38","key":"-20210129","first-page":"42","article-title":"Sirolimus reduces acute rejection after kidney transplantation.","volume":"140","author":"Wasielewski","year":"2000","journal-title":"Deutsche Apotheker Zeitung"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-200407271-00097","article-title":"A prospective, randomized study of cyclosporine (csa)\/mycophenolate mofetil (mmf) versus tacrolimus (tac)\/sirolimus(sir) with rapid discontinuation of prednisone (p) abstract.","volume":"78","author":"Kandaswamy","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"-20210129","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: An interim analysis.","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"suppl 1","key":"-20210129","first-page":"475","article-title":"North\/South American, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with Neoral and corticosteroids abstract.","volume":"1","author":"Kaplan","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"899","article-title":"Everolimus (rad) - 12 month pivotal study results: The efficacy and safety in conjunction with Neoral and steroids abstract.","volume":"12","author":"Kaplan","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl 3","key":"-20210129","first-page":"185","article-title":"Statin therapy in renal transplant patients receiving everolimus: Screening for clinical and pharmacokinetic drug interactions abstract.","volume":"2","author":"Kovarik","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"-20210129","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range.","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.","volume":"3","author":"Kovarik","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 1","key":"-20210129","first-page":"475","article-title":"Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials abstract.","volume":"1","author":"Kovarik","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.","volume":"19","author":"Lorber","year":"2005","journal-title":"Clinical Transplantation"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.","volume":"18","author":"Oberbauer","year":"2005","journal-title":"Transplant International"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007890-200407271-00095","article-title":"Excellent graft function in de novo kidney transplant recipients treated with certican, simulect and reduced neoral exposure: 12-month results abstract.","volume":"78","author":"Eris","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 4","key":"-20210129","first-page":"786","article-title":"Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced neoral exposure and basiliximab: 6 months analysis abstract.","volume":"18","author":"Kramer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"suppl 9","key":"-20210129","first-page":"15","article-title":"Concentration-controlled everolimus (Certican): Combination with reduced dose calcineurin inhibitors.","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"462","article-title":"Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral in de novo kidney transplant recipients: 6 months analysis abstract.","volume":"3","author":"Tedesco","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00959","article-title":"Sirolimus versus cyclosporine in association with mycophenolate mofetil abstract.","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"issue":"7","key":"-20210129","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0041-1345(03)00241-0","article-title":"Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation.","volume":"35","author":"Legendre","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007890-200004271-00976","article-title":"Comparison of long term CSA - and sirolimus-based therapies on lipid parameters abstract.","volume":"69","author":"Legendre","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.","volume":"2","author":"Morales","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"350","article-title":"Comparison of tacrolimus (FK506) and sirolimus(SRL) combination with FK506 and mycophenolate mofetil (MMF) in kidney transplant recipients with steroid avoidance abstract.","volume":"3","author":"Kumar","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"578","article-title":"Comparison of efficacy and safety of sirolimus(slr) and mycophenolate mofetil(mmf) as adjunct to calcineurin inhibitor(cni) based steroid free immunosuppression in kidney transplantation abstract.","volume":"4","author":"Kumar","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"216","article-title":"A prospective randomized study to compare the efficacy and safety of sirolimus (slr) and mycophenolate mofetil (mmf) monitored by protocol biopsies in tacrolimus (tac) based steroid free immunosuppression abstract.","volume":"4","author":"Kumar","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 11","key":"-20210129","first-page":"540","article-title":"12 month results of a randomized trial comparing sirolimus (SRL) versus cyclosporine (CsA) in 150 transplant patients receiving a cadaveric renal graft abstract.","volume":"5","author":"Lebranchu","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"285","article-title":"Preliminary results of a randomized trial comparing sirolimus (srl) versus cyclosporine (csa) in 150 transplant patients receiving a cadaveric renal graft abstract.","volume":"4","author":"Lebranchu","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model.","volume":"2","author":"Blum","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"289","article-title":"Sirolimus (rapamune): Effects on bone in renal transplant patients abstract.","volume":"69","author":"Campistol","year":"2000","journal-title":"Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"880","article-title":"The effect of sirolimus on lipids on renal transplant recipients: Results from clinical trials abstract.","volume":"12","author":"Campistol","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"-20210129","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","article-title":"Rapamycin: Clinical results and future opportunities.","volume":"72","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"suppl","key":"-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00007890-199905150-00196","article-title":"Triglyceride (tg) elevations in renal transplant recipients treated with sirolimus (rapamycin, rapa) added to a cyclosporine (csa)\/prednisone (pred) regimen abstract.","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants.","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology Therapeutics"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"3","key":"-20210129","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0041-1345(01)01987-X","article-title":"Phase III trial of Rapamune versus placebo in primary renal allograft recipients.","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"1-2","key":"-20210129","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0041-1345(00)02317-4","article-title":"Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"Program Abstracts","key":"-20210129","first-page":"698","article-title":"Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients on a cyclosporinerapamycin regimen (phase III protocol 0468602US) abstract.","volume":"9","author":"Sindhi","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program Abstracts","key":"-20210129","first-page":"699","article-title":"A single center 6 month follow up of a phase III trial of sirolimus in a predominantly African-American renal transplant population abstract.","volume":"9","author":"Sindhi","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl","key":"-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00007890-199904150-00949","article-title":"Outcomes of African Americans (AA) in a phase III randomized placebo-controlled trial of sirolimus (SRL) in renal transplantation abstract.","volume":"67","author":"Sindhi","year":"1999","journal-title":"Transplantation"},{"issue":"1-2","key":"-20210129","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0041-1345(00)02421-0","article-title":"A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.","volume":"33","author":"Machado","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"suppl 8","key":"-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00007890-200004271-00163","article-title":"A single-center open label randomized trial of the safety and efficacy of the use of rapamune versus azathioprine in one haplotype living related kidney recipients: preliminary results abstract.","volume":"69","author":"Tedesco","year":"2000","journal-title":"Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(03)00232-X","article-title":"Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.","volume":"35","author":"Tedesco","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007890-200407271-00816","article-title":"Concentration-controlled use of sirolimus (srl) associated with reduced exposure of cyclosporine (csa) in black patients: 12-month results abstract.","volume":"78","author":"Ferreira","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"284","article-title":"Concentration-controlled use of sirolimus (srl) associated with reduced exposure of cyclosporine (csa) in black patients: 12-month results abstract.","volume":"4","author":"Ferreira","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"351","article-title":"Concentration-controlled use of sirolimus (SRL) associated with reduced exposure of cyclosporine (CSA) in black patients abstract.","volume":"3","author":"Machado","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(03)00232-X","article-title":"Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.","volume":"35","author":"Tedesco","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0041-1345(02)03042-7","article-title":"Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.","volume":"34","author":"Burke","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"484","article-title":"Surgical complications after kidney transplantation: Comparing three different immunosuppressive regimens abstract.","volume":"3","author":"Mattiazzi","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl 5","key":"-20210129","first-page":"465","article-title":"Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection abstract.","volume":"3","author":"Miller","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","first-page":"471","article-title":"A phase II, open-label, concentration-controlled, randomized 6-month study of standard-dose tacrolimus sirolimus corticosteroids compared to reduced-dose tacrolimus sirolimus corticosteroids in renal allograft recipients abstract.","volume":"2","author":"Bechstein","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 4","key":"-20210129","first-page":"785","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus sirolimus steroids compared to reduced-dose tacrolimus sirolimus steroids in renal allograft recipients abstract.","volume":"18","author":"Bechstein","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"464","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus sirolimus steroids compared to reduced-dose tacrolimus sirolimus steroids in renal allograft recipients abstract.","volume":"3","author":"Paczek","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"464","article-title":"A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: Combined analysis of the north American target, European and Australian sirolimus-tacrolimus trials abstract.","volume":"3","author":"Whelchel","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.","volume":"26","author":"Kovarik","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"issue":"suppl 8","key":"-20210129","first-page":"296","article-title":"Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral in de novo kidney transplant recipients: 12 months analysis abstract.","volume":"4","author":"Magee","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 4","key":"-20210129","first-page":"786","article-title":"Excellent renal function with concentration-controlled everolimus, reduced exposure to neoral, and steroids in de novo kidney transplant recipients: Results of a 6 months efficacy and safety analysis abstract.","volume":"18","author":"Pascual","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007890-200407271-00713","article-title":"12 month clinical trial results of safety and efficacy of trough-controlled certican dosing with reduced neoral exposure in de novo kidney transplant recipients abstract.","volume":"78","author":"Pascual","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 9","key":"-20210129","first-page":"15","article-title":"Concentration-controlled everolimus (Certican): Combination with reduced dose calcineurin inhibitors.","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"251","article-title":"Pharmacokinetics, safety and efficacy of mycophenolate mofetil in combination with sirolimus vs. cyclosporine in renal transplant patients abstract.","volume":"4","author":"Pescovitz","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Program Abstracts","key":"-20210129","first-page":"916","article-title":"Assessment of renal function in de novo renal transplant patients receiving either sirolimus or everolimus in addition to cyclosporine A abstract.","volume":"12","author":"Rostaing","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program Abstracts","key":"-20210129","first-page":"364","article-title":"The safety and efficacy of reduced- and standard-target concentration tacrolimus plus sirolimus in renal allograft recipients: Preliminary 6-month results from Australia abstract.","volume":"13","author":"Russ","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients.","volume":"35","author":"Russ","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ASN.0000102469.32182.8C","article-title":"Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function.","volume":"15","author":"Stallone","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"suppl 5","key":"-20210129","first-page":"563","article-title":"Sirolimus prolongs delayed graft function in recipients of sub-optimal cadaveric kidney donors abstract.","volume":"3","author":"Stallone","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00007890-200407271-00241","article-title":"The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: A prospective, randomized comparison of tacrolimus and sirolimus abstract.","volume":"78","author":"Dean","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"229","article-title":"Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus abstract.","volume":"4","author":"Dean","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"-20210129","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","article-title":"Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus.","volume":"77","author":"Dean","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"189","article-title":"Frequency of polyomavirus-associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus-based immunosuppression abstract.","volume":"3","author":"Hamad","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"217","article-title":"Metabolic complications after renal transplantation: A comparison of sirolimus vs. tacrolimus-based immunosuppression abstract.","volume":"3","author":"Kudva","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"475","article-title":"Avoiding calcineurin-inhibitors in renal transplantation: A randomized trial of sirolimus vs. tacrolimus abstract.","volume":"3","author":"Larson","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","first-page":"237","article-title":"Kidney transplantation without calcineurin-inhibitors: A randomized trial of sirolimus vs. tacrolimus abstract.","volume":"2","author":"Larson","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"214","article-title":"Obesity increases wound complications in sirolimus-treated renal allograft recipients abstract.","volume":"3","author":"Lund","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0041-1345(03)00226-4","article-title":"Kidney transplantation without calcineurin inhibitors using sirolimus.","volume":"35","author":"Stegall","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"12","key":"-20210129","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/01.TP.0000071301.86299.75","article-title":"A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.","volume":"75","author":"van Hooff","year":"2003","journal-title":"Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1432-2277.2004.tb00426.x","article-title":"Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.","volume":"17","author":"Holmes","year":"2004","journal-title":"Transplant International"},{"issue":"1","key":"-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine.","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clinical Pharmacology Therapeutics"},{"issue":"5","key":"-20210129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.","volume":"3","author":"Kovarik","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.","volume":"19","author":"Lorber","year":"2005","journal-title":"Clinical Transplantation"},{"issue":"suppl 4","key":"-20210129","first-page":"499","article-title":"36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients abstract.","volume":"18","author":"Neumayer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"459","article-title":"36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients abstract.","volume":"3","author":"Oppenheimer","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"suppl 1","key":"-20210129","first-page":"474","article-title":"International, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with neoral and steroids abstract.","volume":"1","author":"Vitko","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"-20210129","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 11","key":"-20210129","first-page":"571","article-title":"Tacrolimus with MMF or two different doses of sirolimus in kidney transplantation: A large randomised multicentre study abstract.","volume":"5","author":"Salmela","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00007890-200407271-00299","article-title":"Tacrolimus in combination with two different sirolimus doses versus a tacrolimus\/mmf-based regimen: A large, randomised clinical study in renal transplantation abstract.","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"issue":"suppl 3","key":"-20210129","first-page":"470","article-title":"A randomized trial of sirolimus vs. cyclosporine in kidney transplantation: Impact on blood cells, lymphocyte subsets, and flow crossmatches abstract.","volume":"2","author":"Flechner","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"suppl 3","key":"-20210129","first-page":"471","article-title":"Sirolimus vs. MMF-first report of a US multicenter kidney transplant study with tacrolimus combination therapy abstract.","volume":"2","author":"Gonwa","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year.","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"issue":"suppl 5","key":"-20210129","first-page":"198","article-title":"A prospective randomized study of cyclosporine (csa)\/cellcept (mmf) vs. tacrolimus (tac)\/sirolimus (sir) with rapid discontinuation of prednisone (p) abstract.","volume":"3","author":"Kandaswamy","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study.","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"issue":"suppl 2","key":"-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007890-200407271-00093","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation abstract.","volume":"78","author":"Oberbauer","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"-20210129","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.","volume":"37","author":"Kramer","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"suppl 8","key":"-20210129","first-page":"297","article-title":"Excellent graft function in de novo kidney transplant recipients treated with certican, simulect and reduced neoral exposure: 12-month results abstract.","volume":"4","author":"Whelchel","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"494","article-title":"Prophylaxis for cytomegalovirus disease in a randomized trial of three different immunosuppressive regimens in renal transplantation abstract.","volume":"4","author":"Ciancio","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"298","article-title":"Everolimus therapeutic concentration range derived from prospective concentration-controlled trial in de novo kidney transplantation abstract.","volume":"4","author":"Kovarik","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"suppl 8","key":"-20210129","first-page":"285","article-title":"Preserving renal function by avoiding calcineurin-inhibitors in renal transplantation: A randomized trial of sirolimus vs. tacrolimus abstract.","volume":"4","author":"Larson","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"-20210129","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.","volume":"5","author":"Vitko","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications.","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clinical Pharmacology Therapeutics"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.tp.0000219703.39149.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:25:52Z","timestamp":1785857152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200605150-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,15]]},"references-count":207,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000219703.39149.85","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,15]]}}}